Literature DB >> 19645542

Surgical treatment of juvenile nasopharyngeal angiofibroma with intracranial extension. Clinical article.

Nevo Margalit1, Oshri Wasserzug, Ari De-Row, Avraham Abergel, Dan M Fliss, Ziv Gil.   

Abstract

OBJECT: The purpose of this study was to describe the surgical treatment and outcomes of patients with intracranial extension of juvenile nasopharyngeal angiofibroma (JNA).
METHODS: Twenty-one patients who underwent operations for JNAs between 1994 and 2008 were enrolled in the study. Seven patients (33%) had intracranial tumor extension. The middle cranial fossa and cavernous sinus were involved in 4 patients who underwent operations via the combined infratemporal fossa-midfacial degloving approach. The anterior skull base was involved in 3 patients who underwent the subcranialmidfacial degloving approach.
RESULTS: Complete tumor removal was achieved in all patients. Postoperative complications included 1 case of soft-tissue infection. None of the patients had tumor recurrence after a mean follow-up of 42 months (range 29-85 months). No adjuvant therapy was required in any patient.
CONCLUSIONS: Combined approaches can be used effectively for treatment of JNAs with intracranial extension without the need for adjuvant therapy.

Entities:  

Mesh:

Year:  2009        PMID: 19645542     DOI: 10.3171/2009.4.PEDS08321

Source DB:  PubMed          Journal:  J Neurosurg Pediatr        ISSN: 1933-0707            Impact factor:   2.375


  3 in total

1.  Nasopharyngeal angiofibroma of the nasal cavity.

Authors:  S Marc Stokes; James T Castle
Journal:  Head Neck Pathol       Date:  2010-05-13

Review 2.  Surgical approaches to resection of anterior skull base and paranasal sinuses tumors.

Authors:  Sara Abu-Ghanem; Dan M Fliss
Journal:  Balkan Med J       Date:  2013-06-01       Impact factor: 2.021

3.  Two types of lateral extension in juvenile nasopharyngeal angiofibroma: diagnostic and therapeutic management.

Authors:  Anna Szymańska; Marcin Szymański; Elżbieta Czekajska-Chehab; Małgorzata Szczerbo-Trojanowska
Journal:  Eur Arch Otorhinolaryngol       Date:  2014-03-06       Impact factor: 2.503

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.